Wolverine Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Wolverine Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-192,103	Closed	-$584K	–	1864
2024 Q4	$584K	Sell	192,103 -39,297	-17%	-$171K	0.01%	839
2024 Q3	$1.2M	Buy	231,400 +228,896	+9,141%	+$1.14M	0.01%	640
2024 Q2	$6.43K	Sell	2,504 -3,000	-55%	-$10.2K	﹤0.01%	1377
2024 Q1	$27.1K	Hold	5,504	–	–	﹤0.01%	1180
2023 Q4	$48.4K	Buy	+5,504	New	+$45.1K	﹤0.01%	1205
2021 Q2	–	Sell	-1,710	Closed	-$47K	–	2455
2021 Q1	$47K	Buy	+1,710	New	+$47.3K	﹤0.01%	1644

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Asset Management's RVNC Position: Q1 2025 in Review

Wolverine Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 192,103 shares — an estimated $584K sold.

Wolverine Asset Management first reported a position in RVNC in Q1 2021 and held it in 6 quarters. The position peaked at $1.2M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Wolverine Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Wolverine Asset Management sold 192,103 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $584K.
Wolverine Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 6 quarters.
Wolverine Asset Management's Revance Therapeutics, Inc. position peaked at $1.2M in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.